Bayer will present new data from two different studies of Adempas (riociguat) for pulmonary arterial hypertension (PAH) at the American College of Chest Physicians (CHEST) 2016 Annual Meeting Oct. 22-26 in Los Angeles.
One of the presentations will be held during the Late-Breaking Abstracts session of the meeting. Bayer will also present data from its efforts to treat non-cystic fibrosis bronchiectasis.
“Our data reflects Bayer’s commitment to advancing the scientific research in diseases of high unmet need, particularly pulmonary arterial hypertension and non-cystic fibrosis bronchiectasis,” Aleksandra Vlajnic, vice president of medical affairs at Bayer, said in a news release.
“We will continue working with physician and patient communities to increase understanding of these diseases and help accelerate time from diagnosis to treatment for these commonly under-detected, and therefore under-treated, pulmonary conditions,” she said.
Data from the study, “Effects of Riociguat in Treatment-Naïve vs. Pretreated Patients with Pulmonary Arterial Hypertension: 2-year Efficacy Results from the PATENT-2 Study,” will be provided in an oral presentation at 5:15 p.m. Oct. 24.
PATENT-2 (NCT00863681) is an open-label Phase 3 long-term extension trial exploring the safety and tolerability of Adempas in PAH patients who completed the PATENT-1 trial (NCT00810693), which was a double-blind, placebo-controlled study. The PATENT-2 study will follow patients for four years and 10 months, but Bayer will release data from two years of treatment comparing the effectiveness of Adempas in patients previously treated for PAH and those who were never treated.
The second oral presentation, “The Relationship between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients with PAH Not Reaching Treatment Goals with Phosphodiesterase 5 Inhibitors,” will offer late-breaking news from the Phase 3 RESPITE study (NCT02007629) at 9:03 a.m. Oct. 25.
RESPITE is an open-label study analyzing whether patients who did not respond to treatment with phosphodiesterase-5 blocking drugs such as Adcirca (tadalafil) could benefit by switching to Adempas. Early data indicated that the switch could improve patient heart function and quality of life.
In both studies, patients received either 1 mg, 1.5 mg, 2.0 mg, or 2.5 mg of Adempas three times a day.
Additionally, Bayer will provide new data on cyprofloxacin dry powder therapy for non-cystic fibrosis bronchiectasis during a Late-Breaking Abstracts session. The presentation, “Efficacy and Tolerability of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in Bronchiectasis (Non-CF Etiology): Results from the Phase III RESPIRE 1 Study,” is at 9:22 a.m. Oct. 25.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?